Pembrolizumab with or without chemotherapy versus chemotherapy for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The phase III KEYNOTE-062 study.

被引：75

作者：

Tabernero, Josep

Van Cutsem, Eric

Bang, Yung-Jue

Fuchs, Charles S.

Wyrwicz, Lucjan

Lee, Keun Wook

Kudaba, Iveta

Garrido, Marcelo

Chung, Hyun Cheol

Salguero, Hugo Raul Castro

Mansoor, Wasat

Braghiroli, Maria Ignez Freitas Melro

Goekkurt, Eray

Chao, Joseph

Wainberg, Zev A.

Kher, Uma

Shah, Sukrut

Kang, SoonMo Peter

Shitara, Kohei

机构：

[1] Vall dHebron Univ Hosp, Barcelona, Spain

[2] Inst Oncol, Barcelona, Spain

[3] Univ Hosp Gasthuisberg, Leuven, Belgium

[4] Katholieke Univ Leuven, Leuven, Belgium

[5] Seoul Natl Univ, Coll Med, Seoul, South Korea

[6] Yale Canc Ctr, New Haven, CT USA

[7] M Sklodowska Curie Mem Canc Ctr, Warsaw, Poland

[8] Seoul Natl Univ, Bundang Hosp, Coll Med, Seongnam, South Korea

[9] Riga East Univ Hosp, Riga, Latvia

[10] Pontificia Univ Catolica Chile, Santiago, Chile

[11] Yonsei Univ, Coll Med, Yonsei Canc Ctr, Seoul, South Korea

[12] Hosp Enfermedad Comun Igss Zona 9, Guatemala City, Guatemala

[13] Christie NHS, Manchester, Lancs, England

[14] Univ Sao Paulo, Inst Canc Estado Sao Paulo, Sao Paulo, Brazil

[15] Univ Canc Ctr Hamburg, Hamburg, Germany

[16] City Hope Comprehens Canc Ctr, Duarte, CA USA

[17] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA

[18] Merck & Co Inc, Kenilworth, NJ USA

[19] Merck & Co Inc, Rahway, NJ 07065 USA

[20] Natl Canc Ctr Hosp East, Dept Gastrointestinal Oncol, Kashiwa, Chiba, Japan

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 18期

关键词：

D O I：

10.1200/JCO.2019.37.18_suppl.LBA4007

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LBA4007

引用

页数：2

共 50 条

[31] Initial data from the phase 3 KEYNOTE-811 study of trastuzumab and chemotherapy with or without pembrolizumab for HER2-positive metastatic gastric or gastroesophageal junction (G/GEJ) cancer
Janjigian, Y.
Kawazoe, A.
Weber, P.
Luo, S.
Lonardi, S.
Kolesnik, O.
Barajas, O.
Bai, Y.
Shen, L.
Tang, Y.
Wyrwicz, L.
Shitara, K.
Qin, S.
Van Cutsem, E.
Tabernero, J.
Li, L.
Shih, C.
Bhagia, P.
Chung, H.
ANNALS OF ONCOLOGY, 2021, 32 : S227 - S227
[32] KEYNOTE-059 Update: Efficacy and safety of pembrolizumab alone or in combination with chemotherapy in patients with advanced gastric or gastroesophageal (G/GEJ) cancer
Wainberg, Z. A.
Jalal, S.
Muro, K.
Yoon, H. H.
Garrido, M.
Golan, T.
Doi, T.
Catenacci, D. V.
Geva, R.
Ku, G.
Bleeker, J.
Bang, Y-J.
Hara, H.
Chung, H. C.
Savage, M.
Wang, J.
Koshiji, M.
Dalal, R.
Fuchs, C. S.
ANNALS OF ONCOLOGY, 2017, 28
[33] Final analysis of the phase III KEYNOTE-585 study of pembrolizumab plus chemotherapy vs chemotherapy as perioperative therapy in locally-advanced gastric and gastroesophageal junction cancer
Shitara, K.
Rha, S. Y.
Wyrwicz, L. S.
Oshima, T.
Karaseva, N.
Osipov, M.
Yasui, H.
Yabusaki, H.
Afanasyev, S.
Park, Y-K.
Al-Batran, S-E.
Yoshikawa, T.
Weber, P. E. Yanez
Di Bartolomeo, M.
Lonardi, S.
Fang, X.
Shih, C-S.
Bhagia, P.
Bang, Y-J.
ANNALS OF ONCOLOGY, 2024, 35 : S213 - S213
[34] A phase 3 study of chemotherapy 1 pembrolizumab vs chemotherapy 1 placebo as neoadjuvant/adjuvant treatment for patients with gastric or gastroesophageal junction (G/GEJ) cancer: KEYNOTE-585-Trial in progress
Bang, Y.
Van Cutsem, E.
Fuchs, C.
Ohtsu, A.
Tabernero, J.
Ilson, D.
Hyung, W.
Strong, V.
Goetze, T.
Yoshikawa, T.
Tang, L.
Hwang, P.
Shitara, K.
ANNALS OF ONCOLOGY, 2018, 29
[35] Pembrolizumab or placebo plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: An updated analysis of KEYNOTE-859 for patients enrolled in Asia.
Yen, Chia Jui
Oh, Do-Youn
Bai, Yuxian
Ryu, Min-Hee
Lee, Jeeyun
Li, Jin
Yang, Lin
Yasui, Hisateru
Yabusaki, Hiroshi
Lam, Ka On
Yamaguchi, Kensei
Yeh, Kun-Huei
Yin, Lina
Leconte, Pierre
Bhagia, Pooja
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 464 - 464
[36] Pembrolizumab (Pembro) or placebo (Pbo) plus chemotherapy (Chemo) for advanced HER2-negative gastric/gastroesophageal junction (G/GEJ) adenocarcinoma (KEYNOTE-859): Asia subgroup analysis
Oh, D-Y.
Bai, Y.
Ryu, M. H.
Lee, J.
Li, J.
Luo, S.
Pan, H.
Qu, Y.
Lu, J.
Yang, L.
Yasui, H.
Yabusaki, H.
Yen, C. J.
Chan, W. W. L.
Yamaguchi, K.
Yeh, K-H.
Yin, L.
Bordia, S.
Bhagia, P.
Rha, S. Y.
ANNALS OF ONCOLOGY, 2023, 34 : S1526 - S1526
[37] KEYNOTE-585: Phase III study of perioperative chemotherapy with or without pembrolizumab for gastric cancer
Bang, Yung-Jue
Van Cutsem, Eric
Fuchs, Charles S.
Ohtsu, Atsushi
Tabernero, Josep
Ilson, David H.
Hyung, Woo Jin
Strong, Vivian E.
Goetze, Thorsten Oliver
Yoshikawa, Takaki
Tang, Laura H.
Hwang, Peggy May Tan
Webb, Nancy
Adelberg, David
Shitara, Kohei
FUTURE ONCOLOGY, 2019, 15 (09) : 943 - 952
[38] Pembrolizumab (pembro) plus chemotherapy (chemo) for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Updated results from the KEYNOTE-859 study
Rha, Sun Young
Wyrwicz, Lucjan S.
Weber, Patricio Eduardo Yanez
Bai, Yuxian
Ryu, Min-Hee
Lee, Jeeyun
Rivera, Fernando
Alves, Gustavo Vasconcelos
Garrido, Marcelo
Shiu, Kai-Keen
Fernandez, Manuel Gonzalez
Li, Jin
Lowery, Maeve Aine
Cil, Timucin
Cruz, Felipe Melo
Oh, Do-Youn
Yin, Lina
Bordia, Sonal
Bhagia, Pooja
Qin, Shukui
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[39] Phase III KEYNOTE-585 study of chemotherapy (Chemo) plus pembrolizumab (Pembro) vs chemo plus placebo as neoadjuvant/adjuvant treatment for patients (Pts) with gastric or gastroesophageal junction (G/GEJ) cancer
Bang, Y-J.
Van Cutsem, E.
Fuchs, C. S.
Ohtsu, A.
Tabernero, J.
Ilson, D. H.
Hyung, W. J.
Strong, V. E.
Goetze, T. O.
Yoshikawa, T.
Tang, L. H.
Hwang, P. M. T.
Adelberg, D.
Shitara, K.
ANNALS OF ONCOLOGY, 2018, 29 : 268 - 268
[40] Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line therapy in patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma
Xu, Rui-hua
Arkenau, Hendrik-Tobias
Bang, Yung-Jue
Denlinger, Crystal S.
Kato, Ken
Tabernero, Josep
Wang, Jin
Li, Jiang
Castro, Henry
Moehler, Markus H.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)

← 1 2 3 4 5 →